Results 31 to 40 of about 349,757 (388)

A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy. [PDF]

, 2015
Although recent methods for the engineering of antibody-drug conjugates (ADCs) have gone some way to addressing the challenging issues of ADC construction, significant hurdles still remain.
Caddick, S, Chester, KA, Chudasama, V, Maruani, A, Miranda, E, Smith, ME   +5 more
core   +1 more source

Antibody–siRNA conjugates (ARC): Emerging siRNA drug formulation

Medicine in Drug Discovery, 2022
Antibody–drug conjugates (ADC) utilizing the targeting properties of antibodies and therapeutic effects of drugs have emerged a rapid development in recent years.
Weiran Cao, Rui Li, Xing Pei, Meihong Chai, Lu Sun, Yuanyu Huang, Jiancheng Wang, Stefan Barth, Fei Yu, Huining He   +9 more
doaj   +1 more source

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Nature Communications, 2020
Antibody-drug conjugates targeting high expression receptors can suffer from poor tumour penetration. Here, the authors use unconjugated antibody to improve the penetration of an antibody-dye conjugate in a clinical study, supporting further clinical ...
Guolan Lu, Naoki Nishio, Nynke S. van den Berg, Brock A. Martin, Shayan Fakurnejad, Stan van Keulen, Alexander D. Colevas, Greg M. Thurber, Eben L. Rosenthal   +8 more
doaj   +1 more source

A Non-Covalent Antibody Complex for the Delivery of anti-cancer drugs [PDF]

, 2019
Antibody drug conjugates (ADCs), which are obtained by coupling a potent cytotoxic agent to a monoclonal antibody (mAb), are traditionally bound in a random way to lysine or cysteine residues, with the final product's heterogeneity having an important ...
Grigoletto, Antonella, Maso, Katia, Monia Montagner, Isabella, Pasut, Gianfranco, Rosato, Antonio, Schiavon, Oddone   +5 more
core   +1 more source

Site-selective protein modification via disulfide rebridging for fast tetrazine/trans-cyclooctene bioconjugation [PDF]

, 2020
An inverse electron demand Diels–Alder reaction between tetrazine and trans-cyclooctene (TCO) holds great promise for protein modification and manipulation.
Chudasama, V., Kuan, S., Nogueira, J., Raabe, M., Weil, T., Xu, L., Zegota, M.   +6 more
core   +1 more source

Development, Validation and Application of a Bridging ELISA for Detection of Antibodies against GQ1001 in Cynomolgus Monkey Serum

Molecules, 2023
Immunogenicity is a major issue associated with the PK, efficacy, and safety evaluation of therapeutic protein products during pre-clinical and clinical studies. A multi-tiered approach consisting of screening, confirmatory, and titration assays has been
Tingting Liu, Yajun Sun, Xiaojie Deng, Lili Shi, Wenyi Chen, Wenjing Fang, Junliang Wu, Xiaotian Fan, Xiaoqiang Chen, Jianhua Sun, Gang Qin, Likun Gong, Qiuping Qin   +12 more
doaj   +1 more source

HER2-targeting Peptide Drug Conjugate with Better Penetrability for Effective Breast Cancer Therapy

BIO Integration, 2023
Antibody-drug conjugates (ADCs) have the following advantages: target specificity; wide therapeutic index; and prolonged circulation half-life. A key limitation of ADCs, however, is the large size (~150 kDa), which markedly slows diffusion through the ...
Yixia Liang, Rong Lei, Jiabao Tan, Junyue Fang, Lin Yu, Shiyu Tan, Yan Nie, Qiongchao Jiang, Xiaoyun Xiao, Phei Er Saw   +9 more
doaj   +1 more source

Strain prioritization and genome mining for enediyne natural products [PDF]

, 2016
The enediyne family of natural products has had a profound impact on modern chemistry, biology, and medicine, and yet only 11 enediynes have been structurally characterized to date.
Ben Shen, Christoph Rader, Dong Yang, Filip Van Nieuwerburgh, Hindra, Huiming Ge, Ivana Crnovčičć, Jeffrey D. Rudolf, Jeremy R. Lohman, Li-Xing Zhao, Qihui Teng, Tingting Huang, Xiangcheng Zhu, Xiaohui Yan, Xiuling Li, Yannick Gansemans, Yanwen Duan, Yi Jiang, Yong Huang   +18 more
core   +2 more sources

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkins Lymphoma: Focus on Brentuximab Vedotin

Clinical Medicine Insights: Oncology, 2012
Hodgkins lymphoma (HL) which has relapsed post or is refractory to autologous bone marrow transplant presents an ongoing treatment challenge. Development of monoclonal antibodies (mAb) for the treatment of HL has aimed to replicate the success of mAb ...
Michelle Furtado, Simon Rule
doaj   +1 more source

Novel method for screening functional antibody with comprehensive analysis of its immunoliposome

Scientific Reports, 2021
Development of monoclonal antibody is critical for targeted drug delivery because its characteristics determine improved therapeutic efficacy and reduced side-effect.
Shusei Hamamichi, Takeshi Fukuhara, Izumi O. Umeda, Hirofumi Fujii, Nobutaka Hattori   +4 more
doaj   +1 more source